Levemir Flexpen

Insulin Detemir, the active ingredient in Levemir Flexpen, is an insulin presented as an injectable solution for subcutaneous use. It provides long‑acting basal insulin therapy for patients with diabetes mellitus type 1 and type 2, helping to maintain stable blood glucose levels. GNH USA supplies Levemir Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levemir Flexpen is a long‑acting insulin analog used in basal insulin therapy for diabetes management. - Diabetes mellitus type 1: provides steady basal insulin to control fasting glucose levels. - Diabetes mellitus type 2: complements oral agents or rapid‑acting insulin to achieve overall glycaemic control. - Basal insulin regimen: used as part of a comprehensive insulin plan to reduce daily glucose variability.

Levemir Flexpen may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase associated with improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged or unconscious episodes requiring assistance. - Anaphylactic reaction: rare systemic allergic response with rash, swelling, or breathing difficulty. - Insulin antibody formation: may alter insulin action or cause hypersensitivity. - Edema: fluid retention leading to swelling of extremities.

When using Levemir Flexpen, several safety considerations are recommended. - Blood glucose monitoring: check levels regularly to adjust dose as needed. - Dose adjustment during illness: reduce or increase insulin based on carbohydrate intake and glucose trends. - Concomitant hypoglycaemic agents: avoid overlapping insulin therapy without medical guidance. - Renal or hepatic impairment: use with caution as clearance may be altered. - Pregnancy and lactation: safety not fully established; consult a healthcare professional. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Flexpen can interact with other medicines, affecting glucose control.

Major Interactions (Avoid): - Other insulin products: combined use may cause severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms, delaying recognition. - Alcohol: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Sulfonylureas or meglitinides: additive glucose‑lowering effect, requiring dose adjustments. - Corticosteroids: may raise blood glucose, necessitating higher insulin doses. - ACE inhibitors or ARBs: can enhance insulin sensitivity, potentially increasing hypoglycaemia risk.